The core danger: the heart
Ibogaine and its metabolite noribogaine block the hERG potassium channel in heart cells. That prolongs the QT interval on an ECG, which can set off torsades de pointes, a dangerous and sometimes fatal arrhythmia. This is not a fringe hypothesis: it is confirmed in human heart-cell studies and runs through essentially all the reported deaths.[1] It is the single most important fact about ibogaine safety, and every credible clinic builds its protocol around it.What the death toll actually tells us
At least 33 ibogaine-associated deaths are documented in the scientific literature.[2] The pattern in those cases is as important as the number: most occurred in people with pre-existing heart disease, those taking other QT-prolonging or cardiac-active drugs, polydrug users, or people treated in settings with no cardiac monitoring or emergency capability. Deaths concentrate among opioid-dependent patients. In other words, the risk is real and it is also patterned and partly modifiable.What reduces the risk
The 2016 clinical guidelines the field uses call for a specific stack of precautions: a pre-treatment 12-lead EKG reviewed for QT interval, electrolyte and liver testing, correcting potassium and magnesium beforehand, ACLS-trained staff and continuous cardiac monitoring during dosing, magnesium loading to protect against torsades, and supervision until the ECG normalizes. The Stanford veteran study used a magnesium protocol and reported no serious cardiac events, which is suggestive that these measures matter.[3] Newer multi-clinic data likewise reports lower mortality under modern screening than historical figures, though that data is largely self-reported.What raises it
Skipping the EKG. Dosing someone with a long QT interval, low potassium or magnesium, or a QT-prolonging medication on board. Combining ibogaine with other cardiac-active or depressant drugs. Treating opioid-dependent patients without monitoring. And the underappreciated one: benzodiazepines, which ibogaine does not detox and which raise seizure risk on top of cardiac risk (see our benzodiazepine page).What this means for you
- The clinic's medical protocol is the product. An EKG before dosing is the floor, not a premium feature. A clinic that skips it is disqualifying.
- Disclose every medication and heart-history detail honestly. The screening only protects you if it is accurate.
- If you have heart disease, a long QT, or take QT-prolonging drugs, ibogaine may be contraindicated for you. See our contraindications page.
- Match the setting to your risk: opioid detox and any cardiac history demand a medical-tier clinic with monitoring, not a retreat.
Sources
- Ibogaine pharmacology scoping review, PMC, 2026
- Legislative Analysis and Public Policy Association, "Ibogaine" briefing, April 2025
- Cherian et al., "Magnesium-ibogaine therapy in veterans with traumatic brain injuries," Nature Medicine, Jan 5 2024
- Brunt et al., cardiovascular safety of ibogaine, Addiction, 2026
Reviewed against primary literature and updated July 2026. This is information, not medical advice.